Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut Neuroendocrine Tumors
KCT0003364Phase 2Recruiting
- Sponsor
- Ipsen
- Start
- Jul 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lanreotide in hindgut neuroendocrine tumor, sponsored by Ipsen. Started Jul 2017; status: recruiting.
02
Drugs
lanreotide
03
Conditions
hindgut neuroendocrine tumor
Beyond the preview
Go deeper on KCT0003364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003364.